About Telomir Pharmaceuticals, Inc. Common Stock
https://telomirpharma.comTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.
CEO
Erez Aminov
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.1M
Value:$1.49M
BLACKROCK, INC.
Shares:291.43K
Value:$393.43K
MILLENNIUM MANAGEMENT LLC
Shares:222.4K
Value:$300.25K
Summary
Showing Top 3 of 36
About Telomir Pharmaceuticals, Inc. Common Stock
https://telomirpharma.comTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.15M ▼ | $-1.1M ▲ | 0% | $-0.03 ▲ | $-1.1M ▲ |
| Q2-2025 | $0 | $5.07M ▲ | $-5.07M ▼ | 0% | $-0.17 ▼ | $-5.07M ▼ |
| Q1-2025 | $0 | $2.19M ▼ | $-2.18M ▲ | 0% | $-0.07 ▲ | $-2.18M ▲ |
| Q4-2024 | $0 | $2.91M ▼ | $-2.9M ▲ | 0% | $-0.1 ▲ | $-2.9M ▲ |
| Q3-2024 | $0 | $6.01M | $-5.99M | 0% | $-0.2 | $-5.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.33M ▲ | $7.4M ▲ | $422.81K ▲ | $6.98M ▲ |
| Q2-2025 | $754.32K ▲ | $829.61K ▲ | $348.39K ▼ | $481.22K ▲ |
| Q1-2025 | $403K ▼ | $491.19K ▼ | $652.29K ▼ | $-161.11K ▼ |
| Q4-2024 | $1.27M ▲ | $1.32M ▲ | $680.97K ▲ | $643.04K ▲ |
| Q3-2024 | $834.64K | $1.04M | $599.91K | $442.07K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.1M ▲ | $-927.26K ▼ | $0 | $7.5M ▲ | $6.57M ▲ | $-927.26K ▼ |
| Q2-2025 | $-5.07M ▼ | $-696.44K ▲ | $0 | $1.05M ▲ | $351.32K ▲ | $-696.44K ▲ |
| Q1-2025 | $-2.18M ▲ | $-863.13K ▼ | $0 | $0 ▼ | $-863.13K ▼ | $-863.13K ▼ |
| Q4-2024 | $-2.9M ▲ | $-605.81K ▲ | $0 | $1.04M ▲ | $431.49K ▲ | $-605.81K ▲ |
| Q3-2024 | $-5.93M | $-1M | $0 | $-46.91K | $-1.05M | $-1M |
CEO
Erez Aminov
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.1M
Value:$1.49M
BLACKROCK, INC.
Shares:291.43K
Value:$393.43K
MILLENNIUM MANAGEMENT LLC
Shares:222.4K
Value:$300.25K
Summary
Showing Top 3 of 36